新型口服头孢菌素ME1207的体外抗菌活性
In vitro antibacterial activity of ME1207, a new oral cephalosporin.
作者信息
Miyazaki S, Miyazaki Y, Tsuji A, Nishida M, Goto S
机构信息
Department of Microbiology, Toho University School of Medicine, Tokyo, Japan.
出版信息
Antimicrob Agents Chemother. 1991 Aug;35(8):1691-4. doi: 10.1128/AAC.35.8.1691.
ME1207 is the prodrug of ME1206. Its in vitro antibacterial activity was compared with that of cefteram, cefpodoxime, cefixime, and cefaclor against various clinical isolates. ME1206 was more active than the other cephems tested against staphylococci, streptococci, Morganella morganii, Pseudomonas cepacia, and Flavobacterium meningosepticum and had the most potent activity against Haemophilus influenzae and Neiserria gonorrhoeae. The drug also showed a wide spectrum of activity against other gram-positive and gram-negative bacteria, except methicillin-resistant Staphylococcus aureus, Enterococcus faecalis, Citrobacter freundii, Pseudomonas aeruginosa, Xanthomonas maltophilia, and Alcaligenes xylosoxydans.
ME1207是ME1206的前体药物。将其体外抗菌活性与头孢特仑、头孢泊肟、头孢克肟和头孢克洛针对各种临床分离株的抗菌活性进行了比较。ME1206在针对葡萄球菌、链球菌、摩根摩根菌、洋葱假单胞菌和脑膜败血黄杆菌的测试中比其他头孢菌素更具活性，并且对流感嗜血杆菌和淋病奈瑟菌具有最强的活性。该药物还对其他革兰氏阳性和革兰氏阴性菌表现出广泛的活性，但对耐甲氧西林金黄色葡萄球菌、粪肠球菌、弗氏柠檬酸杆菌、铜绿假单胞菌、嗜麦芽窄食单胞菌和木糖氧化产碱菌除外。
Zotero 插件